bullish
About the Recent Rebound in China Healthcare and the Future Direction (Updated Top Picks)
181 Views18 Oct 2022 08:55
There's catalyst in medical device sector, leading to the recent rebound, but investors should exit in time before the truth is revealed. After the rally, share price in China healthcare will diverge.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- Interpretation of the 20th National Congress of the CPC and the Impact on China Healthcare24 Oct 2022
- China Healthcare Weekly (Oct.21) - Electrophysiology VBP; Orthodontics VBP New Progress; HPV Vaccine23 Oct 2022
- Microport Scientific (853.HK) - Underperformance Would Be the Norm20 Oct 2022
- About the Recent Rebound in China Healthcare and the Future Direction (Updated Top Picks)18 Oct 2022
- Russia-Ukraine War Episode 2 - The Balance Could Tilt Again and Its Impact on Healthcare Industry12 Oct 2022
- Wuxi Biologics (2269.HK) - Removed from UVL, but the Crisis Is Not Over11 Oct 2022
- About the CXO Plunge After Biden Signed National Biotechnology and Biomanufacturing Initiative19 Sep 2022
x